Management of in- and out-of-hospital screening for hepatitis C.


Journal

Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579

Informations de publication

Date de publication:
2022
Historique:
received: 02 07 2022
accepted: 28 12 2022
entrez: 10 2 2023
pubmed: 11 2 2023
medline: 14 2 2023
Statut: epublish

Résumé

Because of insidious progression and no significant clinical symptoms at early stage, chronic hepatitis C (CHC) is often diagnosed after the occurrence of cirrhosis and hepatocellular carcinoma. Highly effective and low drug resistance of direct-acting antiviral agents (DAAs) have enabled cure of CHC, encouraging the World Health Organization to propose a global viral hepatitis elimination program. To Date, vaccine for CHC is still under research. Therefore, reducing the source of infection is an important means of eliminating CHC other than cutting off the transmission route, which requires screening, diagnosing and treating as many patients in the population as possible. Hospital-based screening strategy have been found to be cost-effective in the management of CHC screening, as reported both nationally and internationally. Currently, China has issued

Identifiants

pubmed: 36761331
doi: 10.3389/fpubh.2022.984810
pmc: PMC9905736
doi:

Substances chimiques

Antiviral Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

984810

Informations de copyright

Copyright © 2023 Zhou, Wang, Li and Chen.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Lancet Gastroenterol Hepatol. 2018 Nov;3(11):778-789
pubmed: 30030068
J Clin Microbiol. 2006 Apr;44(4):1561-3
pubmed: 16597894
Zhonghua Gan Zang Bing Za Zhi. 2021 Apr 20;29(4):319-325
pubmed: 33979957
Clin Mol Hepatol. 2021 Apr;27(2):246-256
pubmed: 33317245
J Virol Methods. 2014 Apr;199:119-23
pubmed: 24487098
Nat Rev Gastroenterol Hepatol. 2013 Sep;10(9):553-62
pubmed: 23817321
MMWR Recomm Rep. 2020 Apr 10;69(2):1-17
pubmed: 32271723
J Hepatol. 2006 Mar;44(3):499-506
pubmed: 16427717
Transfus Med Rev. 2015 Jan;29(1):35-44
pubmed: 25447555
Transfusion. 2005 Feb;45(2):133-40
pubmed: 15660820
J Gen Intern Med. 2018 Apr;33(4):551-557
pubmed: 29352420
AIDS. 2020 Jan 1;34(1):47-52
pubmed: 31789889
Clin Infect Dis. 2019 Nov 13;69(11):1888-1895
pubmed: 30689769
Transfusion. 2005 Dec;45(12):1965-72
pubmed: 16371051
BJOG. 2021 Jan;128(2):304-315
pubmed: 32937015
Clin Res Hepatol Gastroenterol. 2017 Feb;41(1):39-45
pubmed: 27542514
Virol J. 2019 Apr 16;16(1):47
pubmed: 30992019
J Int AIDS Soc. 2019 Aug;22 Suppl 6:e25348
pubmed: 31468692
AJP Rep. 2020 Jan;10(1):e121-e127
pubmed: 32257593
FEMS Microbiol Rev. 1994 Jul;14(3):205-10
pubmed: 8086195
Hepatology. 2006 Apr;43(4):647-9
pubmed: 16557565
J Clin Gastroenterol. 2021 Mar 1;55(3):250-257
pubmed: 32324677
Clin Sci (Lond). 2011 Apr;120(7):287-96
pubmed: 20883210
MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):569-574
pubmed: 32407307
Value Health. 2020 Aug;23(8):1003-1011
pubmed: 32828211
J Viral Hepat. 2021 Feb;28(2):440-444
pubmed: 33184976
Clin Microbiol Infect. 2013 Dec;19(12):E533-41
pubmed: 23902574
J Hepatol. 2021 Mar;74(3):734-741
pubmed: 33248169
J Infect Dev Ctries. 2020 Jun 30;14(6):642-646
pubmed: 32683355
Health Sci Rep. 2021 Jun 04;4(2):e290
pubmed: 34136654
Prev Med. 2020 Sep;138:106153
pubmed: 32473265
Eur Rev Med Pharmacol Sci. 2016 Dec;20(1 Suppl):11-16
pubmed: 28083864
J Intern Med. 2018 May;283(5):500-507
pubmed: 29512219
Zhonghua Gan Zang Bing Za Zhi. 2019 Dec 20;27(12):962-979
pubmed: 31941258
BMC Infect Dis. 2012 Jul 20;12:160
pubmed: 22817275
Sex Transm Infect. 2018 Sep;94(6):443-448
pubmed: 29626174
Vox Sang. 2016 Feb;110(2):196-8
pubmed: 26646317
Transfusion. 1994 Sep;34(9):790-5
pubmed: 8091469
Dig Liver Dis. 2019 Jul;51(7):915-921
pubmed: 31031174
Soc Sci Med. 2008 Mar;66(5):1046-56
pubmed: 18164525

Auteurs

Jing Zhou (J)

Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.

Fa-Da Wang (FD)

Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.

Lan-Qing Li (LQ)

Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.

En-Qiang Chen (EQ)

Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH